California Clinical Trials Report — June 2026

For Californians considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their enrollment deadlines. Across the state, 410 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 95 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers and anxiety are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (11 trials)
• Prostate cancer (9 trials)
• Cancer (8 trials)
• Ovarian cancer (7 trials)
• Anxiety (7 trials)
• Advanced solid tumor (6 trials)
• Gastric cancer (6 trials)
• Pancreatic cancer (5 trials)
• Triple negative breast cancer (5 trials)

Additionally, 5 trials specifically for healthy volunteers are closing soon, providing a final chance to participate in foundational research.

Major Research Initiatives Launch Across California

This month, California welcomes 134 new clinical trials, a decrease from the 163 trials that opened in May 2026. Despite this slight dip, the new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading an important Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This trial aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• Beyond drug trials, observational studies are also making significant contributions. The University of British Columbia is sponsoring NCT07629154, "Smart Discharges for Older Children," an observational multi-country cohort study aiming to build algorithms to identify children at risk of mortality after discharge for sepsis, with 4,000 participants.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study," which plans to enroll 2,748 participants to evaluate the impact of including patient-reported evaluations in cancer treatment recommendations.
• Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer," a prospective, multicenter observational study designed to collect urine and tumor biospecimens from 2,500 patients.

New Research Opportunities Across Conditions and Interventions

The 134 new trials opening this month in California cover a diverse range of health conditions. The most common conditions addressed by these new studies include:

• Chronic pain (5 trials)
• Type 2 diabetes mellitus (5 trials)
• Migraine (4 trials)
• Obesity (4 trials)
• Overweight (3 trials)
• Solid tumor cancer (2 trials)
• Sepsis (2 trials)
• Fatigue (2 trials)
• Myopia (2 trials)
• Opioid use disorder (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 62 of the new studies. Other types of research include behavioral interventions (23 trials), device studies (18 trials), and procedures (10 trials), alongside biological treatments, dietary supplements, radiation, genetic, and diagnostic test studies.

California's Research Hubs and Statewide Reach

California's clinical research landscape continues to be robust, with 5,457 clinical trials currently recruiting across 305 cities and 5,157 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's major metropolitan areas, ensuring broad access for residents. The cities with the most new trials include:

• Los Angeles (31 new trials)
• San Francisco (17 new trials)
• San Diego (16 new trials)
• Palo Alto (10 new trials)
• La Jolla (9 new trials)
• Stanford (7 new trials)
• Walnut Creek (6 new trials)
• Sacramento (6 new trials)
• Duarte (6 new trials)
• Newport Beach (5 new trials)

This distribution highlights the strong presence of research institutions and medical centers across California, from Southern California to the Bay Area and beyond, making participation accessible to a wide population.

Opportunities for All: Healthy Volunteers and Diverse Demographics

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 134 new trials launched this month, 30 are actively seeking healthy volunteers. Statewide, a total of 768 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in California are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 18 include children as participants, and 108 include older adults, ensuring that research benefits diverse age groups. Additionally, 7 new trials are female-only, and 3 are male-only, addressing specific health needs within these populations.

Academic institutions continue to play a vital role in the state's research ecosystem, with the University of California, San Francisco sponsoring 12 of the new trials, and Stanford University sponsoring 11. Other key academic sponsors include the University of California, San Diego (5 trials) and the University of California, Davis (4 trials). Industry sponsors are also driving significant research efforts, with 56 new trials sponsored by pharmaceutical companies such as AstraZeneca, Novo Nordisk A/S, and Pfizer, among others.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across California.